Diabetes Medications Show Promise in Reducing Dementia and Parkinson's Risks

Thursday, 19 September 2024, 03:05

Diabetes medications, specifically SGLT2 inhibitors, may lower the odds for dementia and Parkinson's disease. Recent research indicates that these drugs are associated with significant decreases in risks for Alzheimer's and vascular dementia. A study involving nearly 359,000 individuals with type 2 diabetes reveals compelling evidence supporting this potential health benefit.
Healthday
Diabetes Medications Show Promise in Reducing Dementia and Parkinson's Risks

Recent findings highlight that SGLT2 inhibitors, a class of diabetes medications, may play a critical role in lowering the risk for neurodegenerative diseases such as dementia and Parkinson's disease. This was demonstrated through a study analyzing data from close to 359,000 individuals diagnosed with type 2 diabetes.

The research, published on September 18 in the journal Neurology, indicates that individuals on SGLT2 inhibitors experienced a 20% reduced risk of developing Alzheimer's disease and a 30% lowered risk of dementia linked to vascular issues in the brain.

Dr. Minyoung Lee from Yonsei University College of Medicine in Seoul emphasizes the importance of these findings in a population where diabetes increases the likelihood of cognitive decline. Despite the promising results, further long-term studies are necessary to confirm the lasting protective effects of SGLT2 inhibitors on brain health.

For individuals with diabetes, discussing the option of SGLT2 inhibitors with healthcare providers could potentially lead to improved cognitive health outcomes.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe